How to Respond to an FDA Warning Letter

A warning letter arrives and your first instinct is to fix everything before you write back. That instinct is expensive.

I’ve worked FDA enforcement matters across inspections, recalls, and litigation, and the same pattern keeps showing up. The letter gets treated as a quality chore. Someone in operations drafts the reply, and the company hands a federal regulator a document it can quote back for years.

An FDA warning letter response is a legal filing in everything but name. It enters the agency’s record. Word by word, it can concede elements of a violation and narrow what you are able to argue later.

Our FDA compliance and enforcement defense work starts here. I’ll walk through what FDA asks for in writing and the 15 working days you get to deliver it. Then what the agency does when a reply lands thin.

What an FDA Warning Letter Is, and What Puts You on the List

A warning letter is FDA’s written statement that it believes you violated the Federal Food, Drug, and Cosmetic Act. The agency sends it after it has already judged your facility, your records, or your labels.

It’s advisory. The agency can’t fine you with it and it can’t padlock your line tomorrow, and that reassurance is where companies get into trouble.

The letter is the paper trail the government builds before it goes to court.

Most letters trace back to an inspection. An investigator writes up observations on a Form 483, your company replies or doesn’t, and the district office decides the answer was inadequate.

The triggers are rarely exotic. Sanitation records that don’t reconcile, complaint files nobody closed out, a supplier program that lives only on paper. Or a label claim that turned a food into an unapproved drug.

The errors that most often trigger a letter repeat across the industry, year after year. A repeating problem is a solvable one.

Plenty of companies get letters with no inspection at all. A website claim, a social post, or a shipment stopped at the border can do it. Border stops have become common enough that importers should plan for one.

Importers under the Foreign Supplier Verification Program draw them steadily. Those letters read differently, because the violation is an absent program rather than a dirty floor.

One threshold question decides a surprising amount of what follows. Which agency actually regulates your product?

Meat, poultry, and egg products answer to USDA, and nearly everything else answers to FDA. If that line is fuzzy, start with which agency regulates what.

The 15-Working-Day Clock Starts When the Letter Reaches You

FDA asks for your written answer within 15 working days, and the letters say so in near-identical language every time. A 2026 letter to a produce operation puts it plainly. FDA wants written notice “within 15 working days of receipt of this letter” covering the steps you have taken.

Working days, so weekends and federal holidays drop out. The clock also runs from the day the letter reaches you, rather than the date printed at the top.

Those two details can move your deadline by a week. I’ve watched companies lose real drafting time by counting from the wrong day. It burns a fifth of the window.

Fifteen working days is short for a fix that touches equipment, suppliers, or a validation study. FDA knows that. The letters build in an answer, and most companies never use it.

When corrections can’t be finished in time, FDA asks you to “explain the reason for your delay.” You then say when the rest gets corrected.

One practical note that costs companies nothing. The letter names the compliance officer and the address your reply goes to. I still see replies sent to the investigator who ran the inspection, which slows everything down.

So the deadline is a deadline for replying. Finishing every correction is a separate promise on a schedule of your own making.

Missing the reply date is the version that hurts. Silence reads to a district office as a company that doesn’t intend to fix anything. That impression is hard to undo.

Day one is not for drafting. It’s for pulling the inspection file, the 483 if there was one, every prior response, and the batch and complaint records the letter points at. Counsel reads the cited regulation against what those documents actually say before anyone writes a sentence.

What Goes Into an FDA Warning Letter Response

Read a hundred warning letters and the ask barely changes. Every FDA warning letter response has to carry three things. The specific steps you’ve taken, an explanation of how each one stops the problem from happening again, and paper that shows it happened.

That third element is where most replies thin out. A company describes a new procedure in confident prose and attaches nothing.

What does the reviewer actually check? Documents.

An unverifiable answer gets treated as an answer that never arrived, and nobody is going to call and ask for the attachment you forgot.

Preventing recurrence is the part people read past. Fixing the batch FDA found is the minimum, and a reply that stops there tends to invite a return visit with a closer eye.

The agency is asking what changed in the system that let the batch happen.

You’re also allowed to push back. FDA’s letters say that if you believe you aren’t in violation, you should include your reasoning and supporting information.

That’s a real path. It’s also the one most likely to go wrong without counsel, because a weak disagreement in writing does more damage than none. You rarely get a second chance to frame the same facts.

Why the Reply Should Come From Your Lawyer

Your reply is a written statement to the government, made by a company the government already believes broke the law. That changes what the document is for.

Word choice does real work in it, and “We have corrected the deviation” concedes there was a deviation.

Say a plaintiff’s firm files a class action months later over the same labeling claim. Your own letter becomes an exhibit.

Privilege is the second reason, and companies tend to see it too late. The investigation behind a good reply generates emails, interview notes, and root-cause findings that read very differently in a deposition than in a quality meeting.

Run that work through counsel and much of it can stay protected. Run it through a quality manager’s inbox and it’s discoverable.

An FDA warning letter response drafted by counsel aims at something wider than closing the finding. Quality writes to close the finding.

Counsel writes to close the finding while protecting the arguments you’d need later. An injunction hearing, a False Claims Act matter, or a state attorney general inquiry built on the same facts.

Those goals overlap most of the time. When they don’t, you want to know before the letter goes out.

One more decision belongs to counsel. Who signs the reply, and at what level, tells the district office how seriously the company took the letter. A signature three rungs below the person who can authorize the spending sends the wrong signal.

Drug and device companies carry an extra layer, since one letter can touch marketing claims, quality systems, and reporting duties at once. Our medical products practice handles those matters alongside the food work.

What Happens When a Reply Falls Short

FDA prints the consequence in the letter itself. The standard sentence warns that failure to adequately address any violation “may lead to legal action including, without limitation, seizure and injunction.”

Both are court actions with statutes behind them. Seizure lets the government take custody of the goods under Section 334, the seizure provision.

An injunction goes further and restrains the conduct. The injunction provision of the FD&C Act gives district courts jurisdiction to restrain violations.

Injunction actions usually resolve into a consent decree. Your company agrees to court-supervised terms, often third-party audits, production holds, and government sign-off before a line restarts.

Decrees can run for years. The cost sits in the operating limits rather than any penalty. A plant that cannot restart on its own schedule loses customers it may never win back.

For the full ladder from an inspection to that point, see how FDA enforcement climbs from a 483.

There’s a quieter consequence too. FDA states that once violations turn up during a later inspection or through other means, “enforcement action may be taken without further notice.”

The advisory step you got the first time is a courtesy the agency doesn’t owe you twice.

All of it is public. Warning letters get posted in FDA’s searchable warning letter database, where your customers, your auditors, and your competitors can read them.

Getting the File Closed

A close-out letter is the outcome worth working toward. FDA issues one only after it evaluates what you actually did and finds it enough.

The standard is stricter than most companies expect. Promises earn nothing.

Under FDA’s close-out letter policy, the agency will not issue one “based on representations that some action will or has been taken.” The corrections have to be made and verified. The usual verification is a follow-up inspection.

So your FDA warning letter response in week two sets up an inspection you’ll sit through months later. Write it with that visit in mind, and keep the evidence file current between now and then.

The months in between are where good matters go bad. A company sends a strong reply, the urgency fades, and the investigator comes back to find half the schedule slipped.

Some violations can never be closed out at all. FDA says that where a letter contains violations not correctable by their nature, no close-out letter will issue.

A misbranding claim already in the market can land in that category. The program covers letters issued on or after September 1, 2009.

Where OFW Law usually comes in is the two weeks between the letter landing and the reply going out. We read it against the regulation it cites. We run the internal investigation under privilege, draft the response, and argue about wording that would follow you into litigation.

When a matter has already moved past advisory, we defend it there.

FDA’s procedures for all of this sit in FDA’s Regulatory Procedures Manual, Chapter 4, and we work from the same text the district office does.

The companies that come through these matters intact treated day one as a legal deadline.

Common Questions About FDA Warning Letter Responses

How long do you have to respond to an FDA warning letter?

15 working days from the day the letter reaches your company. Weekends and federal holidays don’t count, and the clock runs from delivery rather than the date printed on the letter. If corrections won’t be finished by then, send your reply anyway with the reason for the delay and the date you’ll complete the rest.

Is a warning letter the same as a Form 483?

No. An investigator hands you a Form 483 at the close of an inspection, and it records what that investigator observed. A warning letter comes later, from the district office or a center, and it states the agency’s position that you violated federal law.

What happens if you ignore an FDA warning letter?

The agency moves from advisory action to court. Its letters name seizure and injunction as the likely next steps. Injunction actions typically end in a consent decree, which can put your operations under court supervision for years.

Can you disagree with FDA in your response?

Yes, and the letters invite it. FDA asks you to include your reasoning and any supporting information if you believe you aren’t in violation. Do it carefully, because a disagreement that misreads the regulation hands the agency a second problem.

Does FDA remove a warning letter once you fix the problem?

The letter stays published. What you can earn is a close-out letter, issued after FDA verifies your corrections, usually through a follow-up inspection. Promised action doesn’t qualify, and where the violations aren’t correctable by their nature, no close-out letter issues at all.